The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of sorafenib mesylate (So) in patients (pts) with evolutive and advanced epithelioid hemangioendothelioma (EHE) or hemangiopericytoma/solitary fibrous tumor (SFT).
Christine Chevreau
No relevant relationships to disclose
Axel Le Cesne
No relevant relationships to disclose
Isabelle Ray-Coquard
No relevant relationships to disclose
Binh Bui Nguyen
No relevant relationships to disclose
Emmanuelle Bompas
No relevant relationships to disclose
Nicolas Isambert
No relevant relationships to disclose
Loic Chaigneau
No relevant relationships to disclose
Jacques-Olivier Bay
No relevant relationships to disclose
Olivier Collard
No relevant relationships to disclose
Ewa Cottura
No relevant relationships to disclose
Julien Domont
No relevant relationships to disclose
Jean-Yves Blay
No relevant relationships to disclose
Charles Fournier
No relevant relationships to disclose
Stephanie Clisant
No relevant relationships to disclose
Eric Gauthier
Employment or Leadership Position - Bayer
Nicolas Penel
Research Funding - Bayer